Lantheus Holdings Inc (NASDAQ:LNTH) has earned an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $20.50.
LNTH has been the topic of a number of research analyst reports. ValuEngine upgraded Lantheus from a “sell” rating to a “hold” rating in a report on Monday, August 20th. BidaskClub downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Tuesday, September 25th.
In other Lantheus news, insider Cesare Orlandi sold 7,055 shares of the company’s stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $18.01, for a total transaction of $127,060.55. Following the transaction, the insider now owns 86,064 shares in the company, valued at approximately $1,550,012.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.
Shares of NASDAQ:LNTH opened at $16.94 on Wednesday. Lantheus has a 1 year low of $12.59 and a 1 year high of $24.45. The stock has a market cap of $668.52 million, a P/E ratio of 20.69, a price-to-earnings-growth ratio of 4.04 and a beta of 1.44. The company has a current ratio of 3.50, a quick ratio of 2.87 and a debt-to-equity ratio of 4.76.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, October 30th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.06. Lantheus had a return on equity of 83.95% and a net margin of 36.75%. The company had revenue of $88.90 million for the quarter, compared to the consensus estimate of $83.53 million. During the same quarter in the previous year, the business earned $0.24 EPS. Lantheus’s revenue was up 11.1% compared to the same quarter last year. On average, analysts expect that Lantheus will post 0.86 earnings per share for the current fiscal year.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Featured Story: What is Liquidity?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.